2023 China Guidelines for Lipid Management

Area of Science:

• Cardiology
• Public Health
• Endocrinology

Background:

• Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in China.
• Elevated low-density lipoprotein cholesterol (LDL-C) is a significant risk factor for ASCVD.
• The increasing burden of ASCVD necessitates updated lipid management strategies.

Purpose of the Study:

• To revise and adapt existing dyslipidemia guidelines into the new "China Guidelines for Lipid Management".
• To provide updated recommendations for lipid control based on global research breakthroughs.
• To establish risk-stratified target LDL-C levels for diverse populations.

Main Methods:

• An Experts' committee adapted the "Guidelines for the prevention and treatment of dyslipidemia".
• The new guidelines utilize cardiovascular disease (CVD) risk stratification to determine target LDL-C values.
• Recommendations include lifestyle modifications, moderate-intensity statin therapy, and additional agents like PCSK9 inhibitors.

Main Results:

• LDL-C remains the primary target for lipid control.
• Initial treatment involves moderate-intensity statins and lifestyle changes.
• Cholesterol absorption inhibitors and PCSK9 inhibitors are recommended as second-line therapies.
• Guidance is provided for lipid management across all age groups, from children to the elderly.

Conclusions:

• The new guidelines aim to comprehensively improve lipid management in China.
• They provide a framework for clinical practice to enhance ASCVD prevention and treatment.
• Risk stratification is crucial for tailoring LDL-C targets and therapeutic strategies.